Form 4: Director Ann Beal Salamone Receives Sanara MedTech Equity

Director Ann Beal Salamone was granted 4,154 shares of restricted common stock by Sanara MedTech Inc. as part of the 2024 Omnibus Long-Term Incentive Plan.

Summary

• Director Ann Beal Salamone acquired 4,154 shares of Sanara MedTech Inc. (SMTI) common stock.
• The shares were granted as restricted stock under the company's 2024 Omnibus Long-Term Incentive Plan.
• The transaction occurred on June 4, 2026, at a price of $0 per share, representing an equity-based compensation grant.
• Following this transaction, the director's total beneficial ownership of common stock increased to 26,858 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership personnel via the 2024 Omnibus Long-Term Incentive Plan.

Negatives

• Minor dilution of existing shareholders due to the issuance of new restricted stock units.

Risks

• Vesting is contingent upon the director providing continued services to the issuer through the vesting date.

Future Outlook

The restricted stock is scheduled to vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term strategic oversight and align board interests with those of public shareholders.

Comparison to Industry Standards

• The use of Omnibus Long-Term Incentive Plans is a standard practice among mid-cap medical technology companies to attract and retain board talent.
• The vesting period of approximately one year is consistent with typical annual director compensation cycles in the healthcare sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the 4,154 restricted shares on or before June 4, 2027.

Key Dates

Keywords

Sanara MedTech, SMTI, Form 4, Insider Trading, Equity Compensation, Director Ownership